AUROBINDO PHARMA Financial Statement Analysis
|
||
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
The Earnings Per Share (EPS) of AUROBINDO PHARMA has increased by 64.62 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
AUROBINDO PHARMA Last 5 Annual Financial Results
[BOM: 524804|NSE : AUROPHARMA]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹24,855 Cr | ₹23,455 Cr | ₹24,775 Cr | ₹23,099 Cr | ₹19,564 Cr |
Expenses | ₹21,137 Cr | ₹19,071 Cr | ₹19,441 Cr | ₹18,234 Cr | ₹15,612 Cr |
Operating Profit (Excl OI) | ₹3,719 Cr | ₹4,385 Cr | ₹5,333 Cr | ₹4,864 Cr | ₹3,952 Cr |
Other Income | ₹291 Cr | ₹323 Cr | ₹381 Cr | ₹192 Cr | ₹155 Cr |
Interest | ₹140 Cr | ₹49 Cr | ₹74 Cr | ₹305 Cr | ₹263 Cr |
Depreciation | ₹1,245 Cr | ₹1,127 Cr | ₹1,055 Cr | ₹967 Cr | ₹668 Cr |
Profit Before Tax | ₹2,613 Cr | ₹3,373 Cr | ₹7,344 Cr | ₹3,743 Cr | ₹3,091 Cr |
Profit After Tax | ₹1,928 Cr | ₹2,647 Cr | ₹5,334 Cr | ₹2,844 Cr | ₹2,365 Cr |
Consolidated Net Profit | ₹1,928 Cr | ₹2,648 Cr | ₹5,335 Cr | ₹2,845 Cr | ₹2,365 Cr |
Earnings Per Share (Rs) | ₹54.16 | ₹32.90 | ₹45.20 | ₹91.05 | ₹48.56 |
PAT Margin (%) | 5.30 | 3.79 | 5.54 | 10.98 | 6.02 |
ROE(%) | 11.18 | 7.50 | 11.38 | 27.53 | 18.52 |
ROCE(%) | 13.76 | 9.39 | 12.71 | 30.10 | 18.72 |
Total Debt/Equity(x) | 0.21 | 0.18 | 0.10 | 0.23 | 0.33 |
Key Financials |
||
Market Cap | : | ₹ 67,381.5 Cr |
Revenue (TTM) | : | ₹ 31,723.7 Cr |
Net Profit(TTM) | : | ₹ 3,515.3 Cr |
EPS (TTM) | : | ₹ 60.5 |
P/E (TTM) | : | 19.2 |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | 0.1% | -5.1% | -6.5% |
SUN PHARMACEUTICAL INDUSTRIES | 0.5% | -0.5% | 14.6% |
DIVIS LABORATORIES | 1.3% | 10.7% | 49.3% |
CIPLA | 2.2% | 0.2% | 2.3% |
TORRENT PHARMACEUTICALS | 2% | -0.8% | 15.7% |
DR REDDYS LABORATORIES | 4.7% | 11.9% | 14.5% |
MANKIND PHARMA | 0.7% | -6.7% | 10.3% |
ZYDUS LIFESCIENCES | 2.4% | 8.6% | -5.9% |
LUPIN | 1.6% | -1.7% | 24.8% |
AUROBINDO PHARMA Revenues
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | 5.97 % |
5 Yr CAGR | 6.17 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹24,855 Cr | 5.97 | |
Mar2023 | ₹23,455 Cr | -5.32 | |
Mar2022 | ₹24,775 Cr | 7.26 | |
Mar2021 | ₹23,099 Cr | 18.07 | |
Mar2020 | ₹19,564 Cr | - |
AUROBINDO PHARMA Operating Profit
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -15.19 % |
5 Yr CAGR | -1.51 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹3,719 Cr | -15.19 | |
Mar2023 | ₹4,385 Cr | -17.79 | |
Mar2022 | ₹5,333 Cr | 9.64 | |
Mar2021 | ₹4,864 Cr | 23.09 | |
Mar2020 | ₹3,952 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -19.96 % |
5 Yr CAGR | -7.23 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 14.96% | -19.96 | |
Mar2023 | 18.69% | -13.19 | |
Mar2022 | 21.53% | 2.23 | |
Mar2021 | 21.06% | 4.26 | |
Mar2020 | 20.2% | - |
AUROBINDO PHARMA Profit After Tax
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | -27.21 % |
5 Yr CAGR | -4.98 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹1,928 Cr | -27.21 | |
Mar2023 | ₹2,648 Cr | -50.36 | |
Mar2022 | ₹5,335 Cr | 87.51 | |
Mar2021 | ₹2,845 Cr | 20.32 | |
Mar2020 | ₹2,365 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 39.84 % |
5 Yr CAGR | -3.13 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 5.3 % | 39.84 | |
Mar2023 | 3.79 % | -31.59 | |
Mar2022 | 5.54 % | -49.54 | |
Mar2021 | 10.98 % | 82.39 | |
Mar2020 | 6.02 % | - |
AUROBINDO PHARMA Earnings Per Share (EPS)
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | 64.62 % |
5 Yr CAGR | 2.77 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹54 | 64.62 | |
Mar2023 | ₹33 | -27.21 | |
Mar2022 | ₹45 | -50.36 | |
Mar2021 | ₹91 | 87.50 | |
Mar2020 | ₹49 | - |
AUROBINDO PHARMA Return on Capital Employed (ROCE)
[BOM: 524804|NSE : AUROPHARMA]
Y-o-Y | 46.54 % |
5 Yr CAGR | -7.41 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 13.76% | 46.54 | |
Mar2023 | 9.39% | -26.12 | |
Mar2022 | 12.71% | -57.77 | |
Mar2021 | 30.1% | 60.79 | |
Mar2020 | 18.72% | - |
AUROBINDO PHARMA Share Price vs Sensex
Current Share Price | : | ₹1,160.2 |
Current MarketCap | : | ₹ 67,381.5 Cr |
Updated EOD on | : | Jun 11,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
AUROBINDO PHARMA | 0.1% |
-5.1% |
-6.5% |
SENSEX | 1.9% |
0.1% |
10.9% |
AUROBINDO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 6.4% | 8.9% | 7.5% |
BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
BSE HEALTHCARE | 3.1% | 5.8% | 23.7% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MIDCAP SELECT | 3.2% | 5.6% | 15.6% |
NIFTY PHARMA | 3.2% | 4.5% | 14.4% |
NIFTY HEALTHCARE INDEX | 3% | 4% | 17.7% |
NIFTY MIDCAP 50 | 3% | 6.1% | 15.4% |
NIFTY MIDSMALL HEALTHCARE | 2.9% | 4.6% | 25.4% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA Financials
How the annual revenues of AUROBINDO PHARMA have changed ?
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
How the Earnings per Share (EPS) of AUROBINDO PHARMA have changed?
The Earnings Per Share (EPS) of AUROBINDO PHARMA has increased by 64.62 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs